Table 1 Baseline clinical characteristics and MG relevant scores in both treatment groups.
Clinical characteristics | Efgartigimod (n = 9) | IVIg (n = 10) | P value |
|---|---|---|---|
Sex, n (%) | |||
Female | 7 (77.78%) | 4 (40.00%) | 0.170 |
Male | 2 (22.22%) | 6 (60.00%) | |
Age at admission, years, mean ± SD | 62.67 ± 19.30 | 55.10 ± 13.14 | 0.327 |
Age at onset, years, mean ± SD | 61.33 ± 18.65 | 54.70 ± 13.08 | 0.378 |
Disease duration, months, mean ± SD | 20.22 ± 26.20 | 6.80 ± 7.08 | 0.170 |
MGFA at administration, n (%) | |||
IIIb | 5 (55.56%) | 6 (60.00%) | 1.000 |
IVb | 4 (44.44%) | 4 (40.00%) | |
Thymoma | 3 (33.33%) | 3 (30.00%) | 1.000 |
Thymectomy | 1 (11.11%) | 0 (0.00%) | 0.474 |
Antibody, n (%) | |||
AChR | 9 (100.00%) | 10 (100.00%) | 0.857 |
RyR | 4 (44.44%) | 3 (30.00%) | |
Titin | 4 (44.44%) | 3 (30.00%) | |
Pyridostigmine at enrollment, n (%) | 9 (100.00%) | 9 (90.00%) | 1.000 |
Immunosuppressive treatment at enrollment, n (%) | |||
Only tacrolimus | 7 (77.78%) | 6 (60.00%) | 0.258 |
Only prednisone | 1 (11.11%) | 1 (10.00%) | |
Tacrolimus and prednisone | 0 (0.00%) | 3 (30.00%) | |
Mycophenolate mofetil and prednisone | 1 (11.11%) | 0 (0.00%) | |
Baseline MG-ADL score, mean ± SD | 13.78 ± 4.18 | 11.00 ± 3.62 | 0.139 |
Baseline MGC score, mean ± SD | 26.44 ± 6.15 | 20.80 ± 7.16 | 0.084 |
